Beginning Radiation Immediately With GammaTile at GBM Excision Versus Standard of Care
A phase 3 trial of Temozolomide in glioma & glioblastoma, run by GT Medical Technologies, Inc., now recruiting.
Overview
Beginning Radiation Immediately With GammaTile at GBM Excision Versus Standard of Care is a phase 3 interventional study registered as NCT07195591 by GT Medical Technologies, Inc., with 766 participants planned, started 2025-12-10 and due to reach its primary completion in 2031-12. Interventions recorded: GammaTile®, External Beam Radiation Therapy and Temozolomide.
Similar pages
not linked directly; found by shared links- TrialA Phase 2b Clinical Study With a Combination Immunotherapy in Newly Diagnosed Patients With Glioblastoma
Shares Temozolomide, Glioma & glioblastoma and the tag pipeline.
- TrialA Study of BPM31510 With Vitamin K1 in Subjects With Newly Diagnosed Glioblastoma (GB)
Shares Temozolomide, Glioma & glioblastoma and the tag pipeline.
- TrialPh I/II Study of NMS-03305293+TMZ in Adult Patients With Recurrent Glioblastoma
Shares Temozolomide, Glioma & glioblastoma and the tag pipeline.
- TrialJK-1201I Combined with Adjuvant Temozolomide in Patients with Newly Diagnosed Glioblastoma Multiforme (GBM)
Shares Temozolomide, Glioma & glioblastoma and the tag pipeline.
- TrialPost-Surgical Stereotactic Radiotherapy (SRT) Versus GammaTile-ROADS (Radiation One and Done Study)
Shares GT Medical Technologies and the tag pipeline.
- TrialSonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM
Shares Temozolomide, Glioma & glioblastoma and the tag pipeline.
- TrialGlioblastoma Treatment With Irradiation and Olaptesed Pegol (NOX-A12) in MGMT Unmethylated Patients
Shares Temozolomide, Glioma & glioblastoma and the tag pipeline.
- TrialSafety and Efficacy of L19TNF Plus Temozolomide Chemoradiotherapy in Patients With Newly Diagnosed Glioblastoma
Shares Temozolomide, Glioma & glioblastoma and the tag pipeline.